Literature DB >> 20655706

The use of mouse models to better understand mechanisms of autoimmunity and tolerance.

Fumi Miyagawa1, Jan Gutermuth, Hong Zhang, Stephen I Katz.   

Abstract

A major emphasis of our studies has been on developing a better understanding of how and why the skin serves as a target for immune reactions as well as how the skin evades becoming a target for destruction. For these studies we developed transgenic mice that express a membrane-tethered form of a model self antigen, chicken ovalbumin (mOVA), under the control of a keratin 14 (K14) promoter. K14-mOVA transgenic mice that express OVA mRNA and protein in the epithelia have been assessed for their immune responsiveness to OVA and are being used as targets for T cells obtained from OT-1 transgenic mice whose CD8+ T cells carry a Vα2/Vβ5-transgenic T cell receptor with specificity for the OVA(257-264)-peptides (OVAp) in association with class I MHC antigens. Some of the K14-mOVA transgenic mice develop a graft-versus-host-like disease (GvHD) when the OT-1 cells are injected while others appear to be tolerant to the OT-1 cells. We found that γc cytokines, especially IL-15, determine whether autoimmunity or tolerance ensues in K14-mOVA Tg mice. We also developed transgenic mice that express soluble OVA under the control of a K14 promoter (K14-sOVA) that die within 5-8 days after adoptive transfer of OT-1 cells and identified these mice as a model for more acute GvHD-like reactions. Spontaneous autoimmunity occurs when these K14-sOVA mice are crossed with the OT-I mice. In contrast, we found that preventive or therapeutic OVAp injections induced a dose-dependent increase in survival. In this review the characterization of 5 strains of K14-OVATg mice and underlying mechanisms involved in autoimmune reactions in these Tg mice are discussed. We also describe a strategy to break tolerance and describe how the autoimmunity can be obviated using OVAp. Finally, a historical overview of using transgenic mice to assess the mechanisms of tolerance is also provided.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655706      PMCID: PMC2956781          DOI: 10.1016/j.jaut.2010.06.007

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  60 in total

Review 1.  Peripheral tolerance of CD8 T lymphocytes.

Authors:  William L Redmond; Linda A Sherman
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

2.  The structure and location of SIMP/STT3B account for its prominent imprint on the MHC I immunopeptidome.

Authors:  Etienne Caron; Renée Charbonneau; Gabrielle Huppé; Sylvie Brochu; Claude Perreault
Journal:  Int Immunol       Date:  2005-11-01       Impact factor: 4.823

3.  Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation.

Authors:  Julie M Curtsinger; Javier O Valenzuela; Pujya Agarwal; Debra Lins; Matthew F Mescher
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

4.  The DRiP hypothesis decennial: support, controversy, refinement and extension.

Authors:  Jonathan W Yewdell; Christopher V Nicchitta
Journal:  Trends Immunol       Date:  2006-07-11       Impact factor: 16.687

5.  The turnover kinetics of major histocompatibility complex peptides of human cancer cells.

Authors:  Elena Milner; Eilon Barnea; Ilan Beer; Arie Admon
Journal:  Mol Cell Proteomics       Date:  2005-11-04       Impact factor: 5.911

Review 6.  T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens.

Authors:  Jens Lohr; Birgit Knoechel; Vijaya Nagabhushanam; Abul K Abbas
Journal:  Immunol Rev       Date:  2005-04       Impact factor: 12.988

7.  Prevention of toxic epidermal necrolysis by regulatory T cells.

Authors:  Hiroaki Azukizawa; Shigetoshi Sano; Hiroshi Kosaka; Yasuyuki Sumikawa; Satoshi Itami
Journal:  Eur J Immunol       Date:  2005-06       Impact factor: 5.532

Review 8.  Expression of class I histocompatibility antigens in defined tissues: effects on T cell function.

Authors:  J F Miller; J Allison; G Morahan; K O Cox; A Mulebacher; R V Blanden
Journal:  Semin Immunol       Date:  1989-11       Impact factor: 11.130

9.  Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage.

Authors:  N Bercovici; A Heurtier; C Vizler; N Pardigon; C Cambouris; P Desreumaux; R Liblau
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

10.  Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface.

Authors:  Andreas O Weinzierl; Claudia Lemmel; Oliver Schoor; Margret Müller; Tobias Krüger; Dorothee Wernet; Jörg Hennenlotter; Arnulf Stenzl; Karin Klingel; Hans-Georg Rammensee; Stefan Stevanovic
Journal:  Mol Cell Proteomics       Date:  2006-10-29       Impact factor: 5.911

View more
  24 in total

1.  In vitro platform establishes antigen-specific CD8+ T cell cytotoxicity to encapsulated cells via indirect antigen recognition.

Authors:  Ying Li; Anthony W Frei; Ethan Y Yang; Irayme Labrada-Miravet; Chuqiao Sun; Yanan Rong; Magdalena M Samojlik; Allison L Bayer; Cherie L Stabler
Journal:  Biomaterials       Date:  2020-06-15       Impact factor: 12.479

2.  T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1.

Authors:  Weici Zhang; Yoko Ono; Yoshinori Miyamura; Christopher L Bowlus; M Eric Gershwin; Emanual Maverakis
Journal:  J Autoimmun       Date:  2011-06-01       Impact factor: 7.094

Review 3.  Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice.

Authors:  David Luckey; Dikshya Bastakoty; Ashutosh K Mangalam
Journal:  J Autoimmun       Date:  2011-05-31       Impact factor: 7.094

Review 4.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

5.  Neoantigen Expression in Steady-State Langerhans Cells Induces CTL Tolerance.

Authors:  Helen Strandt; Douglas Florindo Pinheiro; Daniel H Kaplan; Dagmar Wirth; Iris Karina Gratz; Peter Hammerl; Josef Thalhamer; Angelika Stoecklinger
Journal:  J Immunol       Date:  2017-07-24       Impact factor: 5.422

6.  CD8+ T cell dialyzable extract activity is dependent on TCR and MHC-I.

Authors:  Mark D Kieh; Sandip K Datta; Ian A Myles
Journal:  J Leukoc Biol       Date:  2017-09       Impact factor: 4.962

7.  Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.

Authors:  Naoko Okiyama; Stephen I Katz
Journal:  J Autoimmun       Date:  2014-07-18       Impact factor: 7.094

8.  Soluble peptide treatment reverses CD8 T-cell-induced disease in a mouse model of spontaneous tissue-selective autoimmunity.

Authors:  So Yeon Paek; Fumi Miyagawa; Hong Zhang; Jay T Linton; Shelley B Hoover; R Mark Simpson; Stephen I Katz
Journal:  J Invest Dermatol       Date:  2011-11-17       Impact factor: 8.551

9.  Unique patterns of CD8+ T-cell-mediated organ damage in the Act-mOVA/OT-I model of acute graft-versus-host disease.

Authors:  Barbara Érsek; Nikolett Lupsa; Péter Pócza; Anett Tóth; Andor Horváth; Viktor Molnár; Bence Bagita; András Bencsik; Hargita Hegyesi; András Matolcsy; Edit I Buzás; Zoltán Pós
Journal:  Cell Mol Life Sci       Date:  2016-04-30       Impact factor: 9.261

10.  Spontaneous partial loss of the OT-I transgene.

Authors:  Gretchen Harms Pritchard; Eric W Cross; Marjorie Strobel; Stephen C Jameson; Ross M Kedl; Kristin A Hogquist; Christopher A Hunter
Journal:  Nat Immunol       Date:  2016-05       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.